Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.52 USD
Change Today +0.024 / 4.80%
Volume 376.4K
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

tapimmune inc (TPIV) Snapshot

Open
$0.51
Previous Close
$0.50
Day High
$0.55
Day Low
$0.50
52 Week High
06/23/15 - $1.71
52 Week Low
02/13/15 - $0.12
Market Cap
19.9M
Average Volume 10 Days
1.3M
EPS TTM
$-0.13
Shares Outstanding
38.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAPIMMUNE INC (TPIV)

Related News

No related news articles were found.

tapimmune inc (TPIV) Related Businessweek News

No Related Businessweek News Found

tapimmune inc (TPIV) Details

TapImmune Inc., a clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. The company, in collaboration with Mayo Foundation for Medical Education and Research, is developing HER2/neu, a vaccine technology, which has completed Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which has completed Phase I human clinical trials for the treatment of breast and ovarian cancer. Its products under preclinical stage include Polystart, a nucleic acid–based technology for Her2/neu breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. The company was founded in 1999 and is based in Seattle, Washington.

1 Employees
Last Reported Date: 07/8/15
Founded in 1999

tapimmune inc (TPIV) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $180.0K
Vice President of Development, Member of Scie...
Total Annual Compensation: $15.0K
Compensation as of Fiscal Year 2014.

tapimmune inc (TPIV) Key Developments

Tapimmune, Inc. Appoints John Bonfiglio to Board of Directors

On July 23, 2015, Tapimmune, Inc. appointed Dr. John Bonfiglio to Board of Directors. He was most recently President and CEO of Oragenics.

TapImmune Inc. Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

TapImmune Inc. reported the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast cancer (Stages II-III) that had completed standard treatment (that is surgery, chemotherapy, and Herceptin™) at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine. Twenty-two subjects (age 33 to 69 years) were enrolled. Patients were injected six times over six months with the multi-peptide vaccine and were monitored for toxicity during each visit. Twenty-one patients completed all 6 vaccination cycles. Vaccine induced T-cell immunity was observed in 19 out of 20 evaluable patients. The company recently announced the results of a successful Phase I trial on a Folate Receptor Alpha Vaccine in ovarian and triple negative breast cancer and progression of this program into Phase II clinical trials. TapImmune has an exclusive option to license both the HER2/neu and Folate Receptor Alpha vaccine technologies from Mayo Clinic.

TapImmune, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 03:30 PM

TapImmune, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 03:30 PM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States. Speakers: Glynn Wilson, Executive Chairman, Chief Executive Officer, President, Acting Principal Accounting Officer, Member of Audit Committee and Member of Compensation Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPIV:US $0.52 USD +0.024

TPIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPIV.
View Industry Companies
 

Industry Analysis

TPIV

Industry Average

Valuation TPIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAPIMMUNE INC, please visit www.tapimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.